These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16445830)

  • 1. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
    Rao A; Hills RK; Stiller C; Gibson BE; de Graaf SS; Hann IM; O'Marcaigh A; Wheatley K; Webb DK
    Br J Haematol; 2006 Mar; 132(5):576-83. PubMed ID: 16445830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
    Ravindranath Y; Abella E; Krischer JP; Wiley J; Inoue S; Harris M; Chauvenet A; Alvarado CS; Dubowy R; Ritchey AK
    Blood; 1992 Nov; 80(9):2210-4. PubMed ID: 1384797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
    Tan RM; Quah TC; Aung L; Liang S; Kirk RC; Yeoh AE
    Pediatr Blood Cancer; 2007 Mar; 48(3):262-7. PubMed ID: 16602120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
    Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
    Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
    Hann IM; Stevens RF; Goldstone AH; Rees JK; Wheatley K; Gray RG; Burnett AK
    Blood; 1997 Apr; 89(7):2311-8. PubMed ID: 9116274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
    Stevens RF; Hann IM; Wheatley K; Gray RG
    Br J Haematol; 1998 Apr; 101(1):130-40. PubMed ID: 9576193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
    Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
    Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
    Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
    J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Langkjer ST; Palshof T; Pedersen B; Hokland P
    Eur J Haematol; 2001 Mar; 66(3):160-7. PubMed ID: 11350484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
    Goldstone AH; Burnett AK; Wheatley K; Smith AG; Hutchinson RM; Clark RE;
    Blood; 2001 Sep; 98(5):1302-11. PubMed ID: 11520775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
    Grimwade D; Walker H; Harrison G; Oliver F; Chatters S; Harrison CJ; Wheatley K; Burnett AK; Goldstone AH;
    Blood; 2001 Sep; 98(5):1312-20. PubMed ID: 11520776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
    Uffmann M; Rasche M; Zimmermann M; von Neuhoff C; Creutzig U; Dworzak M; Scheffers L; Hasle H; Zwaan CM; Reinhardt D; Klusmann JH
    Blood; 2017 Jun; 129(25):3314-3321. PubMed ID: 28400376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.
    O'Brien MM; Taub JW; Chang MN; Massey GV; Stine KC; Raimondi SC; Becton D; Ravindranath Y; Dahl GV;
    J Clin Oncol; 2008 Jan; 26(3):414-20. PubMed ID: 18202418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
    Abildgaard L; Ellebaek E; Gustafsson G; Abrahamsson J; Hovi L; Jonmundsson G; Zeller B; Hasle H
    Ann Hematol; 2006 May; 85(5):275-80. PubMed ID: 16518605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.
    Gibson BE; Webb DK; Howman AJ; De Graaf SS; Harrison CJ; Wheatley K;
    Br J Haematol; 2011 Nov; 155(3):366-76. PubMed ID: 21902686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
    Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
    Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia.
    Stevens RF; Hann IM; Wheatley K; Gray R
    Leukemia; 1992; 6 Suppl 2():55-8. PubMed ID: 1578942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
    Marcus RE; Catovsky D; Prentice HG; Newland AC; Chessells JM; Stevens RF; Hann IM; Goldman JM; Hoffbrand AV; Galton DA
    Haematol Blood Transfus; 1987; 30():346-51. PubMed ID: 2442074
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
    Taub JW; Matherly LH; Stout ML; Buck SA; Gurney JG; Ravindranath Y
    Blood; 1996 Apr; 87(8):3395-403. PubMed ID: 8605357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.